Trial Profile

A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pirtobrutinib (Primary)
Indications Multiple sclerosis
Focus Diagnostic use; Therapeutic Use
Sponsors Loxo Oncology

Most Recent Events

25 Mar 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
09 Jan 2024 Planned End Date changed from 5 Sep 2025 to 13 Feb 2026.
09 Jan 2024 Planned primary completion date changed from 24 Jun 2025 to 16 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com